Doering CB - Search Results

1

The Immune Response to the fVIII Gene Therapy in Preclinical Models.

Patel SR, Lundgren TS, Spencer HT, Doering CB. Patel SR, et al. Among authors: doering cb. Front Immunol. 2020 Apr 15;11:494. doi: 10.3389/fimmu.2020.00494. eCollection 2020. Front Immunol. 2020. PMID: 32351497 Free PMC article. Review.

2

High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.

Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB. Gangadharan B, et al. Among authors: doering cb. Blood. 2006 May 15;107(10):3859-64. doi: 10.1182/blood-2005-12-4961. Epub 2006 Jan 31. Blood. 2006. PMID: 16449528 Free article.

3

Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.

Doering CB, Gangadharan B, Dukart HZ, Spencer HT. Doering CB, et al. Mol Ther. 2007 Jun;15(6):1093-9. doi: 10.1038/sj.mt.6300146. Epub 2007 Mar 27. Mol Ther. 2007. PMID: 17387335 Free article.

4

Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.

Ide LM, Gangadharan B, Chiang KY, Doering CB, Spencer HT. Ide LM, et al. Among authors: doering cb. Blood. 2007 Oct 15;110(8):2855-63. doi: 10.1182/blood-2007-04-082602. Epub 2007 Jun 14. Blood. 2007. PMID: 17569821 Free PMC article.

5

Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia.

Doering CB. Doering CB. Methods Mol Biol. 2008;433:203-12. doi: 10.1007/978-1-59745-237-3_12. Methods Mol Biol. 2008. PMID: 18679625

6

Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.

Dooriss KL, Denning G, Gangadharan B, Javazon EH, McCarty DA, Spencer HT, Doering CB. Dooriss KL, et al. Among authors: doering cb. Hum Gene Ther. 2009 May;20(5):465-78. doi: 10.1089/hum.2008.150. Hum Gene Ther. 2009. PMID: 19222367 Free PMC article.

7

Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.

Doering CB, Denning G, Dooriss K, Gangadharan B, Johnston JM, Kerstann KW, McCarty DA, Spencer HT. Doering CB, et al. Mol Ther. 2009 Jul;17(7):1145-54. doi: 10.1038/mt.2009.35. Epub 2009 Mar 3. Mol Ther. 2009. PMID: 19259064 Free PMC article.

8

Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.

Ide LM, Iwakoshi NN, Gangadharan B, Jobe S, Moot R, McCarty D, Doering CB, Spencer HT. Ide LM, et al. Among authors: doering cb. J Gene Med. 2010 Apr;12(4):333-44. doi: 10.1002/jgm.1442. J Gene Med. 2010. PMID: 20209485

9

Advancements in gene transfer-based therapy for hemophilia A.

Doering CB, Spencer HT. Doering CB, et al. Expert Rev Hematol. 2009 Dec;2(6):673-683. doi: 10.1586/EHM.09.63. Expert Rev Hematol. 2009. PMID: 20577574 Free PMC article.

10

Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells.

Doering CB, Archer D, Spencer HT. Doering CB, et al. Adv Drug Deliv Rev. 2010 Sep 30;62(12):1204-12. doi: 10.1016/j.addr.2010.09.005. Epub 2010 Sep 30. Adv Drug Deliv Rev. 2010. PMID: 20869414 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters